Theme: The European perspective of Biologics and Biosimilars

Euro Biosimilars 2016

Renowned Speakers

Euro Biosimilars 2016

5th European Biosimilars Congress 2016 Organizing Committee invites you to attend the largest assemblage of biologics and biosimilars researchers from around the globe during June 27-29, 2016 at ValenciaSpain

European Biosimilars Congress is a global annual event. This European Biosimilars Congress 2016 brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of biosimilars through a decade at Europe finds much requirement for discussion also focussing the latest developments in the field of biologics and biosimilars. A comprehensive approach for the discussion has been taken up as listed below under several tracks and sub-tracks below:

Track 1: Current Challenges of Biologics

The development of biologics calls for overcoming lot many challenges. With initial steps of concepts of biologics, their considerations, essentials for early clinical developments it is very much needed that proper scientific and strategic approaches are taken for the successful development of follow-on-biologics. Moreover, the need for overcoming the challenges continues in the late clinical steps, drug safety factors and labelling requirements. Also it is much required now to develop a drug product in accordance to quality by design (QbD).

This Euro biosimilars conference will look at the multiple facets of current challenges in biosimilar development. This biosimilar conference will focus on multiple aspects of biosimilar product development to successfully deliver safe, potential and efficacious biologic products to the market.

Related Biosmilar Events| Biosimilar Conferences:
7th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit August 29-31, 2016 Atlanta, USA; 7th International Conference and Exhibition on Pharmacovigilance & Clinical Trials September  19-21, 2016 Vienna, Austria; 12th Euro Global Summit on  Cancer Therapy September 26-28, 2016 London, UK; 5th International Conference on Medicinal Chemistry and Computer Aided  Drug Designing December 01-03, 2016 Chicago, USA. BioSim-Asociación Española de Biosimilares , Medicines for Europe(EGA) , GPhA-Generic Pharmaceutical Association , IGBA- International Generic and Biosimilars Medicines Association , BGMA-British Biosimilars Association

Track 2: Emerging Biosimilars in Therapeutics

The explorations in the field of biologics have created a new avenue for the clinicians towards better disease management. The emerging biologics   have already manifested fruitful outcomes in treatment of ailments like those of psoriasis, rheumatic arthritis, certain cancers, inflammatory bowel disease(IBD) etc.

Emerging Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. The main theme of this track is to have sound knowledge in the emerging biosimilars like Recombinant blood products, therapeutic proteins, vaccines, Biosimilar anti-bodies, Growth hormones, Biosimilar peptides, therapeutic proteins and other biosimilar developments.


Related Biologics Conferences| Biologics Meetings:
2nd International Conference and Exhibition on Pain Medicine  May 16-18, 2016 San Antonio, USA ,   Global Summit on Melanoma and Carcinoma July 14-15, 2016 Brisbane, Australia,  4th Global Experts Meeting  Neuropharmacology September 15-17, 2016 San Antonio, USA, 2nd World Congress and Expo. on Medical  Devices  December 01-03, 2016 Baltimore USA, 6th World Congress on Cancer Therapy December  01-03, 2016 Baltimore, USA. 17TH World Conference On Lung Cancer  December 4 – 7, 2016,Vienna, Austria. IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars AssociationBioSim-Asociación Española de BiosimilaresMedicines for Europe(EGA), GPhA-Generic Pharmaceutical Association

Track 3: Biosimilars Analytical Strategies

Analysis of biosimilars and biologics forms to be one of the most important aspect towards the biologics and biosimilar development process. Biosimilars analytical methods for process development and validation as well as use of production technologies such as disposables and supply chain logistics can help companies establish facility flexibility.
This biosimilars global event also includes Bioanalytical methods, FormulationBioassay for comparability and potency testing, GMP protein analysis, LC/MS analysis for discovery, preclinical, and clinical programs.

Related Biosimilar Conferences| Biologics Workshops:
2nd International Meeting on Clinical Case Reports  April 18-20, 2016 Dubai, UAE, 7th World Congress on Bioavailability and Bioequivalence: BA/BE Studies Summit August 29-31, 2016 Atlanta, USA, 5th Global Summit on Toxicology & Applied Pharmacology September 19-21, 2016 Las Vegas, USA, 6th Euro-Global Summit on Toxicology & Applied Pharmacology October 27-29, 2016 Rome, Italy . BGMA-British Biosimilars AssociationBioSim-Asociación Española de BiosimilaresGPhA-Generic Pharmaceutical AssociationIGBAInternational Generic and Biosimilars Medicines AssociationMedicines for Europe(EGA)

Track 4: Regulatory Approach for Biosimilars

Biosimilars are the generic version of biological. It is the new buzz word in pharmaceutical industry. Biosimilars are highly similar to licensed reference product not withstanding minor differences in clinically inactive components; also there are no clinically meaningful differences between the biologicals and the reference product in terms of safety, purity, and potency. This track includes: Licensing of biosimilars, Biosimilars regulation, Patent issues, BLA filing for biosimilars, Biosimilars regulatory prospects of BRIC countries, a paradigm of traditional generics to biosimilars, Biowaiver approval for Biosimilars and other aspects of Biosimilar approvals. European Biosimilars Congress 2016 will provide an excellent and global opportunity to the scientists, partners and pharma leaders from Biopharmaceutical and Biotechnology industries to innovate and to explore the strategic market for Biosimilars and Biologics with a clear picture of the regulatory approach for biosimilars and biologics. 

Related Biologics Meetings| Biosimilars Conferences:

8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems March 07-09, 2016 Madrid, Spain, 18th International Conference on Pharmaceutical Regulatory Affairs Venice, Italy  August 8 - 9, 2016, Brazil Pharma Expo August 29-31, 2016 Sao Paulo, Brazil, 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR September 12-14, 2016 San Antonio, USA, 2nd Annual Congress on Pharma Middle East  October 12-14, 2016, International Conference and Expo on Generic Drug Market and Contract Manufacturing  Oct 31- Nov 02, 2016 Valencia, Spain,  19th International Conference on Pharmaceutical Regulatory Affairs  Doha,Qatar  November 9-10,2017. IGBAInternational Generic and Biosimilars Medicines AssociationMedicines for Europe(EGA), BGMA-British Biosimilars AssociationBioSim-Asociación Española de Biosimilares

Track 5: Legal Issues

 The Patient Protection and Affordable Care Act (PPAC Act) was signed into law in March 2010 in addition to the amendments in the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biosimilars and follow on biologics.  These new statutory provisions are often referred as the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). This track concentrates upon such legal bindings and the aspects of the BPCI Act that pertain to the biosimilars and biologics. This session on legal issues shall be very beneficial to research scientists from both academic backgrounds and also those from industry R&D. The Europe biosimilars, US biosimilars, Australian biosimilars, Canada origin biosimilars and UK biosimilars are expected to take control over the biosimilar market around the globe by 2017.

Related Biosimilar Symposiums| Biologics Conferences:
Industrial Pharmacy April 28-29, 2016 Dubai, UAE, 6th International  Conference and Exhibition on Biologics and Biosimilars October 19-21, 2016 Houston, TX, USA, Drug Formulation  June 06-08, 2016 Beijing ,China,2nd International Conference and Expo on Parenterals & Injectables  December 05-07, 2016 Dallas, TX, USA. BioSim-Asociación Española de Biosimilares , Medicines for Europe(EGA) , GPhA-Generic Pharmaceutical Association , IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars Association

Track 6: Biosimilars Innovator Pharmaceutical Products

Biosimilars is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original biosimilar innovator products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval. This session shall be highly beneficial for the biosimilar manufacturers. This session also finds place for all the biosimilar exhibitions associated with the field of biosimilars and biologics.

Related Biosimilars Meeting| Biologics Symposiums:
Advances in HPLC and Chromatography Techniques March 17-18, 2016 London, UK, Asia Pacific Drug Formulation & Bioavailability Congress June 06-08, 2016 Beijing, China , 7th International Conference and Exhibition on Analytical & Bioanalytical Techniques Sept 29-Oct 01, 2016 Miami, USA, 4th International Summit on GMP, GCP & Quality Control October 26-28, 2015 Hyderabad, India. GPhA-Generic Pharmaceutical AssociationBioSim-Asociación Española de BiosimilaresMedicines for Europe(EGA

Track 7: Globalization of Biosimilars

This track discuses about the generic drugs impact on global biosimilar market and Cost and risk management, Adopting innovative mechanisms such as risk-sharing arrangement, European market for biosimilars.

Those who can attend the biosimilar meeting under this track are ones following Biologics/ Proteins/Biosimilar Products, New Biosimilar Development, Process Science, Biosimilar Market, Portfolio Management, Research & Development, Business Development, Business Operations and Scientific Affairs.

Related Biosimilar Conferences| Biologics Conferences:
8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems March 07-09, 2016 Madrid, Spain,  2nd International Conference and Expo on Drug Discovery & Designing October 24-26, 2016 Istanbul, Turkey. BGMA-British Biosimilars AssociationBioSim-Asociación Española de BiosimilaresGPhA-Generic Pharmaceutical AssociationIGBAInternational Generic and Biosimilars Medicines AssociationMedicines for Europe(EGA)

Track 8: Clinical Studies On Biosimilars

This track includes Clinical trials on major diseases Risk management, and quality affairs, Case studies, and clinical models, Transgenic animals, Targeted cell line development, Clinical biosimilar tracks.docx PK/PD studies, Toxicological studies and Aspects of genotoxicity tests. This track is designed for those who are having sound knowledge on clinical studies and clinicians prospects for biosimilars. Biosimilar guidelines on the above mentioned topics are also to be thrown light upon at this biosimilars conference.

Related Biosimilar Events| Biosimilars Conference:

2nd International Conference on Clinical Trials, August 22-24, 2016 Philadelphia, USA;5th International Conference on Translational Medicine, November 17-19, 2016 San Francisco, USA; 7th International Conference on Biomarkers and Clinical Research, November 28-30, 2016 Baltimore, USA; 4th International Conference on Clinical Pharmacy, October 31-November 01, 2016 Las Vegas, USA;6th International Conference on Clinical and Experimental Cardiology, November 14-16, 2015 San Francisco, USA; 7th International Conference on Pharmacovigilance and Clinical Trials, September 19-21, 2016 Vienna, Austria. BioSim-Asociación Española de BiosimilaresIGBAInternational Generic and Biosimilars Medicines AssociationMedicines for Europe(EGA), BGMA-British Biosimilars Association

Track 9: Intellectual Property Rights

Needless to mention differentially that any pharma product has to successfully pass through the regulatory affairs' scanners before being launched in the market. Biosimilars and biologics are no exceptions. Apart from regulatory aspects the companies developing these biosimilars and biologics tend to enjoy monopoly over their product. Intellectual Property Rights (IPR) and patents are ultimate tools to the biosimilar manufacturers for safeguarding their interests. Pharma  patent scenario, Criteria for patentability and patent claims, Patentable subject matter, biosimilar guidelines, biosimilar patent issues are key points of discussion in the segment. Patent analysts, law firms and legal authorities dealing with biosimilar regulatory affairs would find this conference a perfect platform to put forward their views on the topic.

Related Biologics Events| Biologics Conferences:
8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems  March 07-09, 2016 Madrid, Spain, 6th International Conference and Exhibition on Pharmaceutical Regulatory Affairs and IPR September 12-14, 2016 San Atonio, USA, International Conference and Expo on Generic Drug Market  and Contract Manufacturing  Oct 31- Nov 02, 2016 Valencia, Spain,  19th International Conference on Pharmaceutical Regulatory Affairs  Doha, Qatar  November 9-10,2017. Brazil Pharma Expo August 29-31, 2016 Sao Paulo, Brazil, 18th International Conference on Pharmaceutical Regulatory Affairs, August 8 - 9, 2016, Venice, Italy. IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars AssociationBioSim-Asociación Española de BiosimilaresMedicines for Europe(EGA), GPhA-Generic Pharmaceutical Association

Track 10: Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This also includes Strategies for the bioequivalence assessment of topical dosage forms, Bioequivalence assessment of respiratory dosage forms, Bioequivalence approaches for transdermal dosage forms.

Related Biosimilars Meetings| Biosimilar Conferences:

Back to Basics in Pharmacovigilance  February 18-29, 2016 Whiteley, UK, Asia Pacific Mass Spectrometry  Congress  October 13-15, 2016 Kuala Lumpur, Malaysia, 2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics  June 09-10, 2016 Dallas, USA. 5th Global Summit on Toxicology & Applied Pharmacology  September 19-21, 2016 Las Vegas, USA. BioSim-Asociación Española de Biosimilares , Medicines for Europe(EGA) , GPhA-Generic Pharmaceutical Association , IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars Association

Track 11: BCS and IVIVC Based Biowaivers

Biopharmaceutics Classification System and invitro and invivo classification discusses about ADME pathways of different drugs. This also includes BCS biowaivers, In vitro diffusion cells for dissolution testing in formulation development, In vitro preclinical ADME/BCS testing. The objective of this work was to suggest the biowaivers potential of biopharmaceutical classification system which are known to increase the solubility, dissolution, oral absorption of water insoluble drugs. The European Biosimilars Congress 2016 aims at addressing all such challenges of the pharma formulation sector for biobetters, biologics, biosimilars and biowaivers.

Related Biowaivers Conferences| Biobetters Conferences:
6  Medical Writing and Healthcare Communications Conference April 28-29, 2016 Dubai, UAE. 6th International Conference and Exhibition on Biologics and Biosimilars October 19-21, 2016 Houston, USA. IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars AssociationBioSim-Asociación Española de BiosimilaresMedicines for Europe(EGA), GPhA-Generic Pharmaceutical Association

Track 12 : Biosimilar Market Analysis

This track is concentrated towards the different reviews and forecasts regarding the scenario of Biosimilars market and follow on Biologics. The present status and future scenario of the market are best to be discussed during this session. Market researches from the first launching of biosimilar to the newest one till date prospects for a radical change in the pharmaceutical market. Market researchers, market analysts, industrialists would be the apt participants for this session at Euro Biosimilars 2016.

Track 13:  Biosimilars Pharmacovigilance

This session of the European Biosimilars Congress 2016  looks into the future and FDA initiatives that have already been announced to include enhanced tracking and follow-up of post market issues, planned improvements in AERS, and pilots of new post market drug-monitoring strategies. Current challenges in pharmacovigilance, Adverse drug reactions with pharmaceutical products, Biosimilar guidelines for pharmacovigilance practice and pharmacoepidemiology are the points that shall be laid emphasis in this session.

Related Biosimilar Conferences| Biologics Meetings:

2nd International Conference on Therapeutic Drug Monitoring and Toxicogenomics June 09-10, 2016 Dallas, USA,  2nd International Conference on Clinical Trials August 22-24, 2016 Philadelphia, USA, 5th Global Summit on Toxicology & Applied Pharmacology  September 19-21, 2016 Las Vegas 4th  International Conference on Clinical Pharmacy Oct 31 - Nov 01, 2016 Las Vegas, USA. IGBAInternational Generic and Biosimilars Medicines AssociationMedicines for Europe(EGA), BGMA-British Biosimilars AssociationBioSim-Asociación Española de Biosimilares

Track 14: Plant Produced Biosimilar Products

Biosimilar products are also produced from plants, Production of Biosimilar products in tobacco plants completion of the first step in their research. These also includes Transgenic plants, Post translational genetics, Fermentation culture, Molecular farming. For biosimilar manufacturers this session has the potential to bring up new avenues in their product range. Biosimilars conference is expected to be the best platform for the scientists to share scientific knowledge amongst those biosimilar companies and research institutes who are engaged in biosimilar development pertaining to plant source biosimilars.

Related Biologics Conference| Biosimilar Event:
International Conference on Plant Physiology June 09-11, 2016 Dallas, USA. Plant Biology 2016, July 7-13, 2016, Texas, USA. Plant Biology Europe, June 26-20, 2016 Prague, Czech Republic. BioSim-Asociación Española de Biosimilares , Medicines for Europe(EGA) , GPhA-Generic Pharmaceutical Association , IGBAInternational Generic and Biosimilars Medicines Association , BGMA-British Biosimilars Association

Track 15Entrepreneurs Investment Meet

Entrepreneurs who are willing to put in hard work and invest in the field of biologics and biosimilars will find this meeting the best place to properly shape their drive for the new endeavours. Also this meeting will help them find the best experts who can make their investment fruitful and worthwhile. The best technological knowhow, economical aspects, regulatory red tapes and profit shares involving biosimilars and biologics shall be discussed at this Euro Biosimilars Global Event.

The Euro Biosimilars conference 2016 is owned to bring together the worldwide top pharmaceuticals, biotechnology and regulatory representatives under one roof that will provide them the best platform to update and share knowledge related to biosimilars and biologics. Hence, the International Biosimilar Conference will unfold the multiple facets of biosimilars, ranging from the evolving regulatory landscapes, biosimilar guidelines to the legal and economic aspects and the then current challenges in biosimilar development. This biosimilar conference will focus on a variety of aspects of biosimilar product development to successful delivery of safe, efficacious and potent biosimilar products to the market. By attending this biologics conference one will gain a comprehensive outlook on the key issues surrounding biosimilars. An important platform for Biosimilars stakeholders to discuss and share best practices in expediting development in the field of Biologics and Biosimilars is ought to be Euro Biosimilars 2016.

 

The Organizing Committee  is delighted to invite you to attend the 5th European Biosimilars Congress  one of its remarkable Pharmaceutical conferences, to be held during June 27-29, 2016 in Valencia, Spain. European Biosimilars Congress 2016 brings together scientists, researchers and CROs from around the world. With the approval of second biosimilar by the USFDA-Inflectra the biosimilars market is owned to experience a exponential growth over the coming few years. Many biologics products are making their entry in the pharma market and experiencing a notable rise in their usage over the conventional medications.

At Euro Biosimilars 2016 meet your target audiences from around the world focused on learning about biologics and biosimilars. This conference would be your single best opportunity to reach the largest assemblage of participants from the biologics and biosimilars community.

Why to attend???

Conduct demonstrations, distribute information, meet with current and potential Scientists to update yourself with latest technological advancememts and new research, and receive name recognition at this 3-days' event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in the era of follow-on-biologics and biosimilars are hallmarks of this conference.

Target Audience:

  • Directors, CEO’s of Organizations
  • Business Development Managers
  • Chief Scientific Officers
  • R&D Researchers from Biosimilar and Bioslogics Industries
  • Professors, Associate Professors, Assistant Professors
  • PhD Scholars
  • Patent Attorneys
  • Intellectual Property Attorneys
  • Investment Analysts
  • Association, Association presidents and professionals
  • Noble laureates in Health Care and Medicine
  • Bio instruments Professionals
  • Bio-informatics Professionals
  • Software development companies
  • Research Institutes and members
  • Supply Chain companies
  • Manufacturing Companies
  • CRO and DATA management Companies
  • Training Institutes
  • Business Entrepreneurs
As per market researchers, the global biosimilar market is expected to be worth $24 billion in 2019-at compound annual growth rate (CAGR) of some 65% from 2014.Clinical trials at global level would incur an approximate
cost of few hundred crores.The estimated cost of developing biosimilars for global markets is $75-250 million, while developing traditional non-biologic generics costs about $2-3 million. With the introduction of Inflectra on April 06, 2016 the Biosimilar Market will grow at even higher rate.
 
Critical Analysis:
The capital-intensive nature of the biosimilar business and long gestation periods between initial investment
and commercialization require biosimilar players to take a higher level of risk than their counterparts in the smallmolecule generics business, and this can be a significant barrier to entry for many start-ups.

Importance & Scope:

The European-based pharmaceutical industry makes a major contribution to the Europe, not just in financial terms but also in terms of high-trait employment. Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion in which Spain market is dominated by branded medicines with a share of about 88% value wise which makes it one of the important destinations with top pharmaceutical companies and renowned associations and it is the 4thlargest pharmaceutical market in Europe with a market size of $22.7 billion.

Why Valencia?

Valencia enjoyed strong economic growth over the last decade, much of it spurred by tourism and the construction industry. Many local landmarks were restored, including the ancient Towers of the medieval city (Serrano Towers and Quart Towers), and the San Miguel de los Reyes monastery which now holds a conservation library. The city has numerous convention centres and venues for trade events, among them the Feria Valencia Convention and Exhibition Centre (Institución Ferial de Valencia) and the Palau de congres (Conference Palace), and several 5-star hotels to accommodate business travelers.

There are certain key Pharmaceutical organizations in Spain for eg: Almirall, Zeltia, Esteve, Cinfa Laboratories, Universities and Associations like Society of Hospital Pharmacists of Valencia, Spanish Society of Clinical Pharmacology, Spanish Society of Pharmaceutics and Pharmaceutical Technology, FARMAINDUSTRIA and Spanish Association for the Pharmaceutical Industry in Spain which draw major attention in the field of pharma. According to IMS Health study report, in 2011 Spain became the fourth largest pharmaceutical market in Europe with a market size of $22.7 billion. The Spanish market registered a Compound Annual Growth Rate (CAGR) of ~4.4 per cent during CY2007-CY2011. The revenue of the Spanish generic pharma market stood at $2.20 billion in 2010, which is expected to reach $7.19 billion in 2017, at a CAGR of 18.4 per cent from 2010 to 2017. The market is dominated by branded medicines with a share of about 88 per cent value wise which makes Spain one of the important destinations.

Conference Highlights:

  •  Regulatory Approach for Biosimilars
  •  Emerging Biosimilars in Therapeutics
  •  Clinical Studies On Biosimilars
  •  Globalization of Biosimilars
  •  Biosimilars Innovator Pharmaceutical Products
  •  Biosimilar Analytical Strategies
  •  Bioequivalence Assessment
  •  BCS & IVIVC Based Biowaivers
  •  Plant Produced Biosimilar Products
  •  Pharmacovigilance and its Challenges
  •  Regulatory Affairs and Intellectual Property Rights
  •  Current Challenges in Advancement of Biologics
  •  Biosimilar Companies and Market Analysis
  •  Legal Issues And Implimentation of the BPCI Act

A Unique Opportunity for Advertisers and Sponsors at this International event:

Major Pharma Associations around the Globe

  • Academy of Managed Care Pharmacy (AMCP), Alexandria, VA
  • American Association of Pakistani Pharmaceutical Scientists
  • British Columbia Pharmacy Association
  • California Pharmacists Association
  • Kansas Pharmacists Association
  • Ohio Pharmacists Association
  •  Pharmacy Guild of Australia
  • World Health Organization (WHO)

Major Pharma Associations in Europe

  • European Pharmaceutical Union (EPU)
  • Pharmaceutical Group of the European Union (PGEU)
  • European Association of Employed Community Pharmacists in Europe (EPhEU)
  • Danish Association of Pharmaconomists
  • Norwegian Pharmacy Association

Statistical Analysis of Associations

 

 

Fig 1

 

Figure 1: Statistical Analysis (Reference Source)

Target Audience:

  •  Professors, Associate Professors, Assistant Professors
  •  PhD Scholars
  •  Graduates and Post Graduates
  •  Directors, CEO’s of Organizations
  •  Association, Association presidents and professionals
  •  Noble laureates in Health Care and Medicine
  •  Bio instruments Professionals
  •  Bio-informatics Professionals
  •  Software development companies
  •  Research Institutes and members
  •  Supply Chain companies
  •  Manufacturing Companies
  •  CRO and DATA management Companies
  •  Training Institutes
  •   Business Entrepreneurs

Target Audience:

  •  Industry       60%
  •  Academia     30%
  •  Others           10%

 

 

Fig 1

 

 

Figure 2: Target Audience

Top Universities in Spain:

  •  ESADE Business School
  •  IESE Business School
  •  IE Business School
  •  Universidad Carlos III - Department of Business Administration
  •  EADA Business School

 

 

Fig 1

 

Figure 3: Top Universities in Spain (Reference Source)

Companies Associated With Pharma Activities:

Fig 1

 

Figure 4: Companies Associated with Pharma Activities (Reference Source)

Glance at Market of Pharma:

There are certain key Pharmaceutical organizations in Spain for eg: Almirall, Zeltia, Esteve, Cinfa Laboratories, Universities and Associations like Society of Hospital Pharmacists of Valencia, Spanish Society of Clinical Pharmacology, Spanish Society of Pharmaceutics and Pharmaceutical Technology, FARMAINDUSTRIA and Spanish Association for the Pharmaceutical Industry in Spain which draw major attention in the field of pharma. According to IMS Health study report, in 2011 Spain became the fourth largest pharmaceutical market in Europe with a market size of $22.7 billion. The Spanish market registered a Compound Annual Growth Rate (CAGR) of ~4.4 per cent during CY2007-CY2011. The revenue of the Spanish generic pharma market stood at $2.20 billion in 2010, which is expected to reach $7.19 billion in 2017, at a CAGR of 18.4 per cent from 2010 to 2017. The market is dominated by branded medicines with a share of about 88 per cent value wise which makes Spain one of the important destinations.

Market Growth of Pharma:

Statistics which shows growth in importance of Pharma

Fig 1

 

Figure 5: GlobalPharma growth forecast (Reference Source)

Statistics of Researchers and Academicians working on Pharma: Country Wise

 

Fig 1

 

Figure 6: Most Pharmacists Country wise (Reference Source)

 

Fig 1

 

Figure 7: Least Pharmacists Country wise (Reference Source)

References:

1.   http://www.pharmacy.org/association.html

2.   http://en.wikipedia.org/wiki/List_of_pharmacy_associations#European

3.   http://en.wikipedia.org/wiki/List_of_pharmaceutical_companies

4.   http://pharma.financialexpress.com/sections/market-section/1770-spain-pharma-seeking-new-growth-
      avenues

5.   http://www.abpi.org.uk/industry-info/knowledge-hub/global-industry/Pages/industry-market-.aspx

6.   http://www.worldmapper.org/posters/worldmapper_map217_ver5.pdf

7.    http://en.wikipedia.org/wiki/List_of_pharmacy_schools

I am delighted to be delivering an opening keynote presentation at the 5th European Biosimilars Congress in Valencia this June.

The high cost to associated with entering the market and the size of the biologic drug market make entry attractive but risky. Overall, the financial results from biosimilars have been poor in light of the R&D and manufacturing investments of approximately $1 to $1.5 billion across the seven biosimilar dossiers approved to date. However, there are promising signs. Although biosimilars’ penetration rates, in general, have not been high or consistent across countries or molecules, they are improving. Growth and uptake rates, as well as the number of countries with more than 50 percent penetration, have improved for every new molecule class that has seen biosimilars. The filgrastim class has been the most successful so far, with average volume penetration rates of about 55 percent, and high numbers in many countries.

Twenty-four countries have already approved biosimilars. Some of them, like China and Russia, are not WHO-compliant or have developed a biosimilar-specific development pathway. Biosimilar authorization poses a number of substantial scientific and regulatory challenges for local regulatory authorities.

The clinical requirements vary according to existing knowledge of the reference product and the claimed therapeutic indication(s). Clinical studies are necessary to demonstrate comparative efficacy. Special attention should be devoted to immunogenicity, which must always be investigated for all products with due consideration to risks associated with different indications.

I look forward to discussing these themes in my presentation on Immunogenicity in Biosimilars and its role in biosimilar development at the meeting, as well as learning about developers’ and regulators’ solutions to these numerous challenges.

 

Dr. Candida Fratazzi

BBCR Consulting, Cambridge MA, USA

 

Biosimilars-2014

OMICS Group’s 3rd International Conference and Exhibition on Biowaivers, Biologics and Biosimilars at Hyderabad International Convention Center, Hyderabad, India during October 27-29, 2014 was organized with a focus on Critical Review on “Current Challenges and Opportunities in Cost Effective and Affordable Biosimilars” was a great success where eminent keynote speakers from various reputed companies made their resplendent presence and addressed the gathering.

Biosimilars-2014 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various newfangled topics related to the field of Biowaivers, Biologics and Biosimilars.

OMICS Group International would like to convey a warm gratitude to all the Honorable guests and Keynote Speakers of Biosimilars-2014:

Nigel Rulewski, Quintiles Inc., USA
Mohan Dewan, R.K. Dewan & Co., India
Steven Lehrer, Cipla Ltd., USA
Heike Schoen, LUMIS International GmbH, Germany
Krishna Menon, Cellceutix Corporation, USA
Rodeina Challand, PRA Health Sciences, UK
Daniel Galbraith, BioOutsource Ltd., UK
Kamali Chance, Quintiles Inc., USA

OMICS Group, on behalf of the conference, congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors. We would like to thank the Poster Competition Judge Dr. Rodeina Challand, PRA Health Sciences, UK and Dr. Rajiv Dahiya, Association of Pharmacy Professionals, India for their valuable time.

Best Poster Winners: 
Anjaneyulu Narapusetti, JNTU-K, India
Rapaka Naga Kishore, JJT University, India
Syeda Sumayya Siraj, Deccan School of Pharmacy, India
Mohammed Nooman, Deccan School of Pharmacy, India
Sufiyan Ahmad, Association of Pharmacy Professionals, India
K Malawika Maheshwari, Doctor of Pharmacy Association, India

OMICS Group also took the privilege of felicitating Biosimilars-2014 Organizing Committee, Keynote Speakers, Chair and Co-Chairs whose support made conference a great success.

With the enormous feedback from the participants and supporters of Biosimilars-2014, OMICS Group Conferences is glad to announce 4th International Conference and Exhibition on Biologics and Biosimilars October 26-28, 2015 Baltimore, USA

 


Past Reports  Gallery  

Biosimilars-2013

2nd International Conference and Exhibition on Biowaivers & Biosimilars was successfully organized by OMICS Group on September 23-25, 2013 at Raleigh, North Carolina, USA. Outstanding response and active participation was received from the researchers, leaders from regulatory, pharmaceutical R&D sectors, and principal investigators. Organizing Committee Members & Editorial Board Members of OMICS Group helped in making this meeting a grand success.

The theme of this event “Addressing Novel Strategic Considerations for Biosimilar Market”covered a broad range of vitally important sessions that covered the way to exchange ideas and perspectives on the challenges in this field.

The conference proved to be the most important gathering for Pharma leaders, in competing to bring affordable medicines to market and establishment of insightful case studies and in-depth market analysis for the fast-growing of Biosimilars.  

Keynote sessions were preceded by eminent speakers:

Dr. Michael Retsky, Harvard School of Public Health, USA
Dr. Ivo Abraham, University of Arizona, USA
Dr. Russell Reeve, Quintiles Inc., USA
Dr. Arturo Solis Herrera, Human Photosynthesis Study Center, Mexico
Dr. Rodeina Challand, PRA International, UK

OMICS Group International conveys its wishes for the support of various organizations and delegates from all around the world. And our sincere admiration to our Event exhibitor: FeF Chemicals for their determined efforts towards manufacturing and supply high purity products, and BioPort Folio (USA), ChemLinked (China) & Lab Bulletin (USA) for its efforts in promoting this event throughout its network.

With grand success of Biosimilars-2013 in USA, OMICS Group International is proud to announce "3rd International Conference and Exhibition on Biowaivers & Biosimilars” during October 27-29, 2014 in Hyderabad, India.

Coming together is a beginning; keeping together is progress; working together is success.

We wish to lead a way to a fabulous event.

 

 

Past Reports  Gallery  

Biosimilars-2012
The International Conference and Exhibition on Biowaivers & Biosimilars, hosted by theOMICS Group was held during September 10-12, 2012 at Hilton San Antonio Airport, USA. Generous response and active participation were received from the Editorial Board Members of OMICS Group Journals as well as from scientists, researchers and leaders from pharma, government organizations, students who made this conference as one of the most successful and productive events in 2012 from OMICS Group.


The conference was carried out through various sessions, in which discussions were held on the following scientific tracks: 

  • Biosimilars: Innovator Pharmaceutical Products
  • Biosimilars: Regulatory Approach
  • Skill Set for Biosimilars Development
  • Clinical Studies
  • Biosimilars Therapeutics
  • Commercialization or Globalization of Biosimilars
  • Plant Produced Biosimilar Products
  • Aggregation and Immunogenicity of Biosimilars
  • BCS & IVIVC Based Biowaivers
  • Analytical Strategies

The response to the International Conference and Exhibition on Biowaivers & Biosimilars was huge and was attended by about less than 200 delegates representing 30 countries from different corners of the world. 

The conference was initiated with a series of invited lectures delivered by both Honorable guests and members of the Keynote forum. The list included Carmine Lanni Bioanalytical Development Services, USA; Brian Dorn, Barnes & Thornburg LLP, USA; Laszlo Endrenyi, University of Toronto, Canada; David Goodall, Paraytec Limited, UK; Indu S. Javeri, CuriRx Inc., USA; Lisa J. Murray, Absorption Systems, USA; Paul A. Calvo, Sterne, Kessler, Goldstein & Fox P.L.L.C., USA; Michael McLean, PlantForm Corporation, Canada. 

All the above mentioned Honorable guests and Keynote speakers gave their energetic and fruitful contributions at Biosimilars-2012

All accepted abstracts have been indexed in OMICS Group Journal of Bioequivalence & Bioavailability as a special issue. The theme of this conference was on "A Synergistic Approach towards Biowaivers & Biosimilars". Based on this, speaker's discussions included many recommendations. 

We are also obliged to various outside experts, company representatives and other eminent personalities who supported the conference by facilitating the discussion forums. Our sincere thanks to Organizing Committee Members for their gracious presence, support and assistance towards Biosimilars-2012, and with their unique feedback, OMICS Group would like to announce the "2nd International Conference and Exhibition on Biowaivers & Biosimilars" to be held at Hilton, Raleigh-NC, USA during September 23-25, 2013


Past Reports  Gallery  

Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 27-29 , 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Day 1 Day 2 Day 3
Poster Opportunity Available

Media Partners

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
eurobiosimilars@conferenceseries.com
Sponsors / Exhibiting / Advertising.
eurobiosimilars@omicsgroup.com
General Queries.
eurobiosimilars@conferenceseries.net

View Proceedings of Previous Conferences

Biosimilars 2015 Proceedings
Biosimilars 2014 Proceedings
Biosimilars 2013 Proceedings
Biosimilars 2012 Proceedings
Authorization Policy

By registering for the conference you grant permission to Conferenceseries LLC to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.